Langelie Biologicals Pharma Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
- Paid Up Capital ₹ 1.00 M
- Company Age 15 Year, 5 Months
- Last Filing with ROC 31 Mar 2024
- Revenue Growth -9.03%
- Profit Growth 113.75%
- Ebitda 608.25%
- Net Worth 0.88%
- Total Assets 3.82%
About Langelie Biologicals Pharma
Langelie Biologicals Pharma Private Limited (LBPPL) is a Private Limited Indian Non-Government Company incorporated in India on 10 August 2009 and has a history of 15 years and five months. Its registered office is in Patna, Bihar, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 1.00 M, as per Ministry of Corporate Affairs (MCA) records.
Vivek Sinha, Manish Kumar, Alpana, and One other member serve as directors at the Company.
Company Details
-
Location
Patna, Bihar, India
-
Telephone
+91-XXXXXXXXXX
-
Email Address
-
Website
-
-
Social Media-
Corporate Identity Details
-
CIN/LLPIN
U24230BR2009PTC014749
-
Company No.
014749
-
Company Classification
Private Limited Indian Non-Government Company
-
Incorporation Date
10 Aug 2009
-
Date of AGM
30 Sep 2024
-
Date of Balance Sheet
31 Mar 2024
-
Listing Status
Unlisted
-
ROC Code
Roc Patna
Industry
Who are the key members and board of directors at Langelie Biologicals Pharma?
Executive Team (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Manish Kumar
|
Managing Director | 10-Aug-2009 | Current |
Board Members (3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
|
Vivek Sinha
|
Director | 10-Aug-2009 | Current |
|
Alpana
|
Director | 25-May-2016 | Current |
|
Madhumita Kumari
|
Director | 01-Nov-2019 | Current |
Financial Performance of Langelie Biologicals Pharma.
Langelie Biologicals Pharma Private Limited, for the financial year ended 2022, experienced Minor drop in revenue, with a 9.03% decrease. The company also saw a substantial improvement in profitability, with a 113.75% increase in profit. The company's net worth moved up by a moderate rise of 0.88%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Langelie Biologicals Pharma?
In 2021, Langelie Biologicals Pharma had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
-
Paramhans Institue Of Neurology LlpAlpana is a mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Langelie Biologicals Pharma?
Unlock and access historical data on people associated with Langelie Biologicals Pharma, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Langelie Biologicals Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Langelie Biologicals Pharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
